Bad phosphorylation as a target of inhibition in oncology

Ngoc Linh Chi Bui, Vijay Pandey, Tao Zhu, Lan Ma, Basappa, Peter E. Lobie

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


Bcl-2 agonist of cell death (BAD) is a BH3-only member of the Bcl-2 family which possesses important regulatory function in apoptosis. BAD has also been shown to possess many non-apoptotic functions closely linked to cancer including regulation of glycolysis, autophagy, cell cycle progression and immune system development. Interestingly, BAD can be either pro-apoptotic or pro-survival depending on the phosphorylation state of three specific serine residues (human S75, S99 and S118). Expression of BAD and BAD phosphorylation patterns have been shown to influence tumor initiation and progression and play a predictive role in disease prognosis, drug response and chemosensitivity in various cancers. This review aims to summarize the current evidence on the functional role of BAD phosphorylation in human cancer and evaluate the potential utility of modulating BAD phosphorylation in cancer.

Original languageEnglish (US)
Pages (from-to)177-186
Number of pages10
JournalCancer Letters
StatePublished - Feb 28 2018


  • Apoptosis
  • BAD phosphorylation
  • Bcl-2 family
  • kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Bad phosphorylation as a target of inhibition in oncology'. Together they form a unique fingerprint.

Cite this